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Background: Myoblasts are capable of forming muscle fibers after transplantation and 22 
are therefore envisioned urinary incontinence treatment after radical prostatectomy. 23 
However, the safety of this treatment and its interactions with putative remaining 24 
neighboring cancer cells has not yet been investigated. 25 
Objective: To determine the safety of myoblast transplantation for the treatment of 26 
post-prostatectomy stress urinary incontinence by analyzing microenvironmental 27 
interactions between myoblasts and prostate carcinoma cells in vitro and in vivo. 28 
Design, Setting and Participants: Myoblasts isolated from rectus abdominis of 29 
patients undergoing abdominal surgery were co-cultured with prostate cancer cells and 30 
subcutaneously co-injected with tumor cells in vivo. 31 
Outcome Measurements and Statistical Analyses: Cell proliferation, cycle arrest 32 
and apoptosis of cancers in co-culture with myoblasts were performed. Tumor volume 33 
and metastasis formation were evaluated in a mouse model. Tissue specific markers 34 
were assessed by immunohistochemistry, FACS analyses, Western blot and RT-35 
qPCR. Outcome was statistically analysed by independent samples t-tests, one-way-36 
ANOVA and Pearson Correlation. 37 
Results and Limitations: In this study we have demonstrated that myoblasts, in 38 
proximity of tumor, provide paracrine TNFα to their microenvironment, decreasing 39 
tumor growth of all prostate cancer cell lines examined. Co-culture experiments 40 
showed induction of cell cycle arrest, tumor death by apoptosis and increased 41 
differentiation of myoblasts. This effect was in large parts blocked by TNFα inhibition. 42 
The same outcome was demonstrated in a mouse model, where co-injected human 43 
myoblasts also inhibited tumor growth and metastasis formation of all prostate cancer 44 
cell lines evaluated. This research is based on established models for cancer research. 45 
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However, the complex interactions between stromal and tumor cells were not 46 
addressed. 47 
Conclusions: Our results suggest that differentiating MPCs restrict tumor growth and 48 
limit metastasis formation by paracrine TNF-a secretion and support the safety of 49 
cellular therapy using myoblasts for muscle reconstruction, even in the proximity of 50 




TAKE HOME MESSAGE 53 
Differentiating MPCs restrict tumor growth and limit metastasis formation by 54 
paracrine TNF-a secretion. This Indicates that the treatment of post prostatectomy 55 
urinary incontinence with autologous myoblasts is safe, even in patients with 56 





Skeletal muscle comprises nearly 50% of the human body, is richly vascularized but 60 
rarely the site of cancer metastases. The cellular and molecular mechanisms 61 
underlying this phenomenon are not yet understood[1]. An intrinsic protective 62 
mechanism avoiding ingrowth of metastatic cells and formation of new tumors seems 63 
to be present. Simultaneously, skeletal muscles are the source of myoblasts[2], 64 
which are capable of regenerating muscle fibers, and therefore are investigated for 65 
the treatment of several muscular dysfunctions, including stress urinary incontinence 66 
(SUI)[3], a frequent complication after radical prostatectomy[4]. Preclinical studies 67 
have demonstrated that myoblasts, when implanted in the urinary sphincter, 68 
efficiently recover continence [5]. The pelvic floor is also a frequent site of residual 69 
prostate cancer cells[6], but until now no investigations targeted cell fate and possible 70 
interactions between myoblasts and vicinal preexisting cancer. 71 
Parallels have long been drawn between stem cells and cancer cells. In fact, both 72 
cell types share common features such as capacity for self-renewal, differentiation 73 
potential, relative quiescence, resistance to drug and toxins, resistance to apoptosis, 74 
secretion of growth factors and stimulation of angiogenesis by production of vascular 75 
endothelial growth factor (VEGF)[7]. These features could result in two possible 76 
outcomes: Cell proliferation or cell death. For instance, the presence of VEGF, which 77 
is secreted by many stem cells and progenitor cells including myoblasts[8], has the 78 
potential to promote prostate cancer angiogenesis leading to enhanced tumor growth 79 
and bone metastasis[9]. On the other hand, myoblasts are activated by 80 
inflammation[2] and use inflammatory cytokines to perform and regulate their cross-81 
talk for activation and differentiation[10]. These same inflammatory cues, paracrine 82 
secreted by myoblasts, could triggers cancer apoptosis. 83 
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A recent study successfully demonstrated inhibited growth of melanoma cells in the 84 
presence of myoblasts, but failed to describe a possible intercellular mechanism that 85 
explains this cell behavior [11]. Upon differentiation, myoblasts secrete tumor 86 
necrosis factor alpha (TNFα), which plays a key role in myoblast activation and 87 
differentiation, thereby linking inflammation to muscle regeneration[12]. In tumor 88 
cells, TNFα activates two parallel pathways, nuclear factor-κB (NF-κB) or c-Jun N-89 
terminal kinase (JNK). If NF-κB is activated, TNFα acts as a growth promoter, 90 
stimulating proliferation and metastasis. However, if JNK is turned on, a Caspase3-91 
dependent-apoptosis-pathway leads to cell death[13]. In this study, we demonstrate 92 
that myoblast-secreted-TNFα is capable of influencing vicinal prostate carcinoma by 93 
inducing cell cycle arrest and apoptosis in vitro and in vivo. Additionally, despite the 94 
proximity to prostate cancer, myoblasts will rapidly differentiate into well-organized 95 
myotubes. Cell-therapy with myoblasts might provide an ideal treatment of post-96 
prostatectomy urinary incontinence by improving sphincter function and inhibiting 97 




MATERIAL AND METHODS 100 
 101 
Cell Isolation and Culture 102 
Upon ethical-approval and informed-consent, myoblasts were isolated from rectus 103 
abdominis biopsies of male patients (60-80 y) undergoing abdominal surgery. 104 
Biopsies were immediately processed according to established protocols[14] and 105 
cells were expanded until passage 2 (P2) with a medium change every third day. Cell 106 
characterization was performed by cellular growth rate, FACS analyses, 107 
Immunocytochemistry, gene expression assay (RT-QPCR) and Western Blot. Muscle 108 
tissue formation was assessed by injecting 5 million myoblasts with a collagen carrier 109 
into the subcutaneous space of nude-mice. Tissues were retrieved after three and six 110 
weeks for histological analysis. 111 
The three prostate carcinoma cell lines (ATCC-LGC Standard) were chosen 112 
according to their increasing clinical aggressiveness. They are retrieved from lymph 113 
node ( LNCaP)[15], bone (PC3) [16], and brain (DU145) metastasis[17]. An 114 
aggressive vulvar leiomyossarcoma cell line (SK-LMS1) served as an additional 115 
cancer control [18]. An indirect co-culture model (BD Falcon™) was applied, where 116 
cells shared culture medium (DMEM enriched with 10% fetal bovine serum (FBS) 117 
and 1% streptomycin/penicillin) thereby exchanging their cellular products without 118 
direct cell-cell-contact. Cells were co-cultured for 10 day with medium change every 119 
third day, and analyses performed at four time points (days 1, 4, 7 and 10). TNFα 120 
was neutralized with a mouse monoclonal anti-TNFα antibody (Sigma, T-6817). 121 
 122 
Growth Rate and Fiber Formation Assay (FFA)  123 
Cells were trypsinized and hemocytometer cell counts were performed on triplicates, 124 
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averaged and growth curves were plotted by time (days). In all cases, triplicate 125 
samples of log phase cells were plated at a density of 5x103cells/cm2. Cell viability 126 
was confirmed by toluidine blue staining. The formation of myofibers was examined 127 
on slide chambers and after 8 days in differentiating condition myofibers were fixed 128 
(methanol, 7min), stained (1:20 Giemsa, 1h) and air dried. Images were taken with a 129 
Leica-Imager-M1 Microscope. Five high-power-fields (HPF) were analyzed and data 130 
expressed as fused cells in myofibers/HPF, number of fibers/HPF and cells per fiber. 131 
 132 
FACS Analyses 133 
Cells were immunolabeled by overnight incubation with anti-Pax7 (1:200,Sigma), 134 
anti-MyoD (1:100,BDPharmingen), anti-desmin (1:50,BDBiosciences), anti-MyHC 135 
(1:4,DSHB) and anti-sarcomeric-α-actinin (1:1000,Sigma) and one hour with FITC-136 
Goat-Anti-mouse-IgG/IgM antibody (2ng/µl,BDBiosciences). A total of 50’000 events 137 
were recorded by FACSCanto flow-cytometer (BDBiosciences) immediately after 138 
labeling and data analyzed using FlowJo (7.1.3,Tree Star Inc.). All data are 139 
expressed as percent positive cells as defined by flow-cytometry. 140 
 141 
Western Blot 142 
Cells were washed with PBS/protease inhibitor (Sigma) and lysed with lysis buffer 143 
(50mM Tris-HCl, 150mM NaCl, 10% glycerol, 1% Triton X-100, 2mM EDTA, 40mM ß-144 
glycerophosphate, 50mM sodium-fluoride, 10µg/ml leupeptin, 10µg/ml aprotinin, 1µM 145 
pepstatinA, 1mM PMSF). Samples were centrifuged (10min, 13000rpm), and proteins 146 
determined in the supernatant. Total protein was measured using DC™ Protein-147 
Assay (Bio-Rad), and 30 µg of protein lysate was loaded on 12% Biorad gels. 148 
Proteins were transferred onto PVDF-membranes (Millipore), blocked (1h, 5% non-149 
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fat-dry-milk), and incubated (4°C, overnight) with anti-Desmin (1:100,BD 150 
Biosciences), anti-MyH (1:6,DSHB), anti-TNFα (1:500,Sigma), anti-p21WAF1 151 
(1:1000,Calbiochem), Cleaved Caspase-3-Asp175 (1:1000,Cell- Signaling) and anti-152 
GAPDH (1:2000,Sigma). Membranes were washed (TBS-0.1% Tween-20, 30min), 153 
incubated with HRP-conjugated secondary antibody (TBS-0.1% Tween-20, 5% non-154 
fat-dry-milk, 1 h) and developed by an ECL-technique (ECL-Kit, Amersham). 155 
 156 
RT-qPCR 157 
RNA extraction, cDNA preparation and RT-qPCR reactions were done using 158 
Taqman® gene expression assay kits (Applied Biosystems), according to 159 
manufacture’s protocols. Data were normalized with 18S expression, quantitatively 160 
analyzed by quantification cycles (Cq) and fold changes[19] and graphically 161 
represented in amplification plots. MIQE guidelines were followed. 162 
 163 
In vivo Experiments and Tumor Size Determination 164 
Myoblasts and tumor cells were cultured as described above, mixed in a collagen 165 
carrier (1mg/ml) and bilaterally injected into the dorsal subcutaneous space of 8 166 
nude-mice (i.e. 16 samples) per group. Cell-cell interactions in vivo were examined 167 
on day 21 and 42 after injection in nine groups: four with co-injected 5x106 myoblasts 168 
and 2.5x106 cancer cells (LNCaP, PC3, DU145 and SK-LMS), four controls of the 169 
respective tumors with 2.5x106 cancer cells alone, 1 myoblast control with 5x106 170 
cells. The experiments were performed in time course triplicates and repeated with 171 
four different patient myoblasts samples. Tumor volume and growth was measured 172 
and volume was calculated according to the formula mm3=a2xb/2 [20]. Tumor/sample 173 
size, myoblast differentiation, tumor aggressiveness and metastasis (lymph node, 174 
  
10 
lung and liver) were assessed after three and six weeks by histological staining of 10 175 
µm thick frozen sections. Histomorphometric analysis was performed using the MBF 176 
software “IMAGEJ for microscopy”. 177 
 178 
Histological Staining and Immunocytochemistry 179 
Cells/tissues were fixed (4% PFA,10min, RT), permeabilized (0,5% Triton, 7min), 180 
blocked (5% BSA/0,1% Triton, RT, 30min) and immunolabelled with anti-Pax7 181 
(1:200,Sigma), anti-MyoD (1:100,BDPharmingen), anti-desmin (1:50,BDBiosciences), 182 
anti-MyH (1:4,DSHB) and anti-sarcomeric actinin (1:1000,Sigma), and incubated 1 183 
hour with anti-mouse-IgG-Cy3 (Sigma). Digital images were taken with a Leica 184 
Imager M1 Microscope. Tissues were also stained with Hematoxylin and eosin (HE) 185 
by incubating slides in hematoxylin (10min, water rinse 2min), dipping in 1% acid 186 
alcohol and Eosin, and dehydrating with consecutive EtOH (70%, 96%, 100%) and 187 
Xylol dips. 188 
 189 
Statistics 190 
Presented data are expressed as averages with corresponding standard deviation. 191 
Analyses by independent samples t-tests, one way ANOVA or Pearson Correlation 192 
were done with SPSS v20 (SPSS Inc, Chicago, IL). Graphics were drawn on the 193 





Myoblasts differentiate and cancer cells undergo cell cycle arrest and apoptosis in 197 
co-culture in vitro 198 
Human myoblasts were successfully isolated and characterized by FACS, 199 
Immunocytochemistry (ICC) and Fiber Formation Assay (FFA). The cell population 200 
expressed 76.5 ± 2.3% PAX-7, 60.6 ± 6.3% MyOD, and 81.6 ± 2.5% desmin. After 201 
four days of co-culturing human myoblasts (Figure 1A, 1B) and prostate carcinoma 202 
cell lines in vitro (Figure 1C, 1D), myoblasts displayed a decreasing growth rate 203 
(Figure 1E), fused and developed muscle fibers and, therefore increasing (Figure 1F) 204 
their differentiation ratio (p<0.001). While only 4.2 ±1.0% of the control myoblasts 205 
formed muscle fibers, the differentiation ratio of myoblasts increased in parallel to the 206 
respective prostate cancer line aggressiveness (p=0.011), with rates of 11.5 ±5.5% in 207 
LNCaP, 14.5 ±6.9% in PC3 and 25.3 ±2.3% in DU145. Conversely, cancer cell lines 208 
significantly decreased (p<0.001) their growth rate (Figure 1G). The decrease in 209 
cancer cell growth was due to cell cycle arrest and apoptosis (Figure 1H), as 210 
demonstrated by Western Blot and RT-QPCR for Caspase 3 and p21WAF.  211 
 212 
TNFα-dependent induction of cell cycle arrest and apoptosis in cancer cell lines co-213 
cultured with myoblasts. 214 
Myoblasts demonstrated a striking, up to 25 fold, increase of TNFα mRNA when 215 
exposed to tumor (Figure 2A), which lead to significantly higher amounts of TNFα 216 
(p<0.001) into the conditioned-medium in the co-culture system (Figure 2B). The 217 
myoblast-TNFα-secretion in co-culture increased gradually according to the 218 
corresponding prostate carcinoma aggressiveness (p<0.001), significantly correlating 219 
(Pearson: 0.754, p<0.001) with the myoblast differentiation ratio (Figure 2C). Yet, the 220 
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presence of prostate cancer induced higher autocrine-TNFα-secretion by myoblasts, 221 
leading to robust muscle fiber formation. Furthermore, TNFα-antibody blocking 222 
decreased the myoblast differentiation ratio and permitted cancer growth de novo 223 
(Figure 2D) by reducing Caspase3 and p21WAF mRNA and protein expression to 224 
control-levels (Figure 2E). The myoblast-secreted-TNFα concentration negatively 225 
correlated to cancer cell growth (p<0.001, Pearson value -0.58) suggesting that 226 
myoblast-paracrine-TNFα is sufficient to induce significant cancer growth inhibition. A 227 
parallel assay demonstrated that cancer cell lines alone do not reach detectable 228 
levels of TNFα RNA or protein expression. 229 
 230 
Myoblast restrain tumor growth inducing cancer apoptosis and cell cycle arrest in vivo 231 
Interactions between myoblasts and prostate cancer were further investigated in vivo 232 
by co-injecting myoblasts and tumor cells subcutaneously in nude-mice (Figure 3A). 233 
All co-injected samples reduced tumor growth (p<0.05), while tumor injected alone 234 
kept growing widely (Figure 3A, 3B). Although, no systemic metastasis could be 235 
detected, prostate carcinoma infiltrated local lymph nodes (Figure 3C). Lymph node 236 
micrometastasis were significantly reduced in co-injected groups (10,9%), when 237 
compared to control (90,6%).These results demonstrate that myoblasts collaborate to 238 
restrict prostate cancer to its primary site, thus significantly (p<0.001) reducing 239 
metastasis. 240 
The extent to which myoblasts influenced cancer occurred gradually again following 241 
cancer aggressiveness (Figure 4). Histomorphometric distance analyses 242 
demonstrated that the tumor areas closer to the newly formed muscle underwent 243 
apoptosis and cell cycle arrest more intensely (Pearson values -0.91 and -0.86 244 
respectively) supporting the hypothesis that soluble factors are responsible for the 245 
  
13 
antitumor effects (Figure 5). Despite the evident changes in tumor behavior, muscle 246 
tissue developed a well-organized and differentiated structure in vivo. We could not 247 
detect any changes in muscle phenotype in the presence of tumor, which also 248 





Cell-cell interactions play a crucial role in tissue formation, regeneration processes 252 
and inflammatory reactions. Cellular signalling between neighboring cells is based on 253 
two main mechanisms: Growth modulation by endogenous secretion of active 254 
compounds and cell competition. These two mechanisms have been well 255 
documented in fibroblasts, which are capable of secreting growth factors and other 256 
peptides, thus delivering cues to neighboring cells. Fibroblasts isolated from breast 257 
tumoral areas are permissive allowing breast cancer metastasis, whereas fibroblast 258 
from normal breast tissue restrict tumor growth[21]. Cell competition has also been 259 
proposed to regulate early cancer stages, when developing cancer cells overcome 260 
genomic constraints[22]. It triggers apoptosis within and around tumors  by promoting 261 
rivalry between different anaplastic and normal cell lineages[23].  262 
In this context, myoblasts also present key intercellular signaling products that allow 263 
cross-talk required for myogenesis and new fiber formation upon muscle injury[24]. 264 
We demonstrated that myoblasts produce increased TNFα levels in the presence of 265 
tumor cells, stimulating muscle differentiation and inducing cancer cell death. 266 
Myoblasts secrete higher TNFα levels when differentiating and this paracrine-267 
secretion evokes microenvironmental changes, which control muscle regeneration by 268 
activating Pax7 in quiescent myoblasts and thereby induce differentiation and muscle 269 
formation[12]. We have demonstrated that myoblasts in co-culture with cancer cells 270 
increaseTNFα-secretion, inducing apoptosis  in vitro and in vivo. TNFα bound to 271 
TNFR-1 receptor triggers Caspase-3 activation leading to an apoptotic cascade and 272 
cell death[25]. The dual effect of TNFα inducing differentiation in myoblasts and 273 
apoptosis in tumors can be explained by two parallel pathways: activation of p38α 274 
and c-Jun N-terminal kinase (JNK). Once p38α is activated, Pax7 initiates 275 
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myogenesis and myoblast differentiation[12] and, by activating the JNK pathway, 276 
triggers cancer apoptosis through a Caspase-3-dependent pathway[13]. A further line 277 
of action of TNFα in cancer inhibition affects tumor vascularity, probably due to 278 
higher response to TNFα in tumoral vessels by receptor up-regulation (TNFR-1)[25]. 279 
These observations suggest that small amounts of TNFα delivered by differentiating 280 
myoblasts can be enough to induce tumoral anti-vascular effects. 281 
This research was based on established models for cancer research, however the 282 
complex interactions between stromal and tumor cells were not addressed. We 283 
demonstrated that myoblast-secreted-TNFα levels increase according to tumor 284 
aggressiveness, in accordance with previous findings correlating prostate cancer 285 
Gleason-score and inflammatory response to endogenous cytokines[26]. The 286 
presence of inflammatory factors related to muscle regeneration plays a role in 287 
myoblast-secreted-TNFα regulation[12]. This leads to the hypothesis that specific 288 
inflammatory cues delivered by the prostate tumor stimulate neighboring myoblasts 289 
to produce higher TNFα levels. A potential pathway is the increase of TACE 290 
production due to stress and nutrient shortage, leading to increased release of 291 
endogenous TNFα by muscle cells [27]. We anticipate that investigations targeting 292 
cancer-mediated-stress factors on muscle cells will be the focus of future efforts 293 
towards a better understanding of interactions between cancer and Adult Stem Cells, 294 




Myoblasts can be isolated from muscle biopsies of patients, rapidly grown in culture, 297 
implanted into the site of injury and thereafter form functional muscle within weeks. 298 
Our results indicate that differentiating myoblasts secret TNFα inducing apoptosis 299 
and cell cycle arrest in Prostate cancer. These characteristics make myoblasts 300 
promising cell source for muscle reconstruction, even in the proximity of cancer. 301 
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FIGURE LEGENDS 381 
 382 
 383 
Figure 1 – Co-culture effects on myoblasts and cancer cells. Cell growth rate, 384 
differentiation ratio, morphology and gene expression were influenced by co-culture. 385 
Myoblasts differentiated rapidly in the presence of tumor, significantly increasing 386 
differentiation ratio (A, B, F) and, consequently, decreasing cell growth (E). Prostate 387 
carcinoma and sarcoma cells significantly decreased in growth (C, D, G) and 388 
underwent apoptosis and/or cell cycle arrest (C, D, H). Desmin staining in co-culture 389 
(A) and control (B), Caspase 3 staining of DU145 cells in co-culture with myoblasts 390 
(C) and control (D), cytoskeleton labelled in green (Phalloidin 488) and secondary 391 
antibody in red (Cy3). Caspase 3 and p21 mRNA fold increase and protein 392 
expression (H) significantly increased when compared to tumor control (dashed 393 
line=1.0). Samples in co-culture with myoblast were represented as (+ Mb) and 394 
control without myoblasts as (- Mb). mRNA fold increase was normalized with 18S 395 
reference gene (*p<0.001, **p=0.005, ***p=0.011) 396 
 397 
Figure 2 – Myoblast secreted TNFα induce myoblast differentiation and inhibit 398 
cancer cell line growth rate by inducing apoptosis and cell cycle arrest. (A) RT-399 
QPCR assay demonstrates myoblast mRNA expression increase on the fourth day of 400 
co-culture with different cancer cell lines. A significant difference could be found 401 
between different prostate cancer cell lines, increasing according to tumor 402 
aggressiveness. (B) Myoblasts TNFα secretion increases according to the cancer 403 
aggressiveness in co-culture. CM: conditioned Medium. (C) Myoblast differentiation 404 
ratio correlate (Pearson correlation: 0.754) to the amount of produced TNFα . (D) 405 
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Cell growth rate of cancer (LNCaP, PC3, DU145 and SK.LMS-1) was assessed by 406 
cell counting at day 1, 4, 7 and 10 of co-culture. All cancer cell lines showed a 407 
significant decrease in growth in the presence of myoblasts (bold lines), when 408 
compared to control (fine line). Cancer growth rate was in great part recovered 409 
(dashed lines) after TNFα neutralization. (E) Apoptosis and cell cycle arrest are 410 
triggered in all cancer cells co-cultured with myoblasts. Again TNFα blocking in 411 
conditioned medium reverse in great part these effects. Caspase 3 and p21 tumor 412 
control mRNA fold increase is represented with a dashed line (=1.0). (*p<0.001, 413 
**p<0.05). 414 
 415 
Figure 3 – Tumor growth and lymph node metastasis was reduced in vivo in 416 
samples co-injected with myoblasts. (A) 21 days after subcutaneous cell injection, 417 
tumor size was measured and a significant tumor size difference was found between 418 
co-injected and control samples. On day 42, myoblast co-injected tumor mass 419 
shrank, whereas control samples kept growing. (B) Final tumor size at day 42 was 420 
significantly smaller in myoblast co-injected samples. (C) Axillar lymph node 421 
metastasis assessment was performed by analysis of macro- and micrometastasis 422 
with H&E, Desmin and cytokeratin staining, positive lymph nodes. Ratio of axillar 423 
metastasis was also significantly reduced (p<0.001) in all tested cancers, when co-424 
injected with myoblasts. Samples co-injected with myoblasts were represented as (+ 425 
Mb) and control without myoblasts as (- Mb). *p<0.05, **p=0.009, ***p=0.002 426 
 427 
Figure 04 – Histological aspect of subcutaneously injected tumor in vivo. At day 428 
42, HE staining demonstrates a tendency of newly formed muscle and cancer tissue 429 
(first row) to growth in clusters, with differentiated muscle areas impairing growth of 430 
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neighbor tumor masses. In opposition, control cancers (second row) grow freely 431 
forming bigger and complex tumor masses. Increasing Caspase3 and p21WAF 432 
expression was detected in all tumors in samples co-injected with myoblasts. 433 
Samples co-injected with myoblasts were represented as (+ Mb) and controls are 434 
cancer cell lines injected without myoblasts (-Mb). In the co-injected samples muscle 435 
is represented with a “M” and cancer tissue areas with a “C”. DAPI (blue), anti-mouse 436 
IgG Cy3 (red), and the injected myoblasts were labelled in vitro with PKH 67 (green). 437 
Muscle on 438 
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Figure 05 – Histomorphometric analyses of co-injected tumor with myoblasts. 440 
Histomorphometric analysis demonstrates a significant increase on apoptosis (A) and 441 
cell cycle arrest (B) in all tested tumors. (C) Three tumor areas were analyzed 442 
according to distance of newly formed muscle. The total positive area, calculated by 443 
fluorescence intensity, demonstrated a gradient of Caspase 3 and p21 expression in 444 
all cancers tested. These directly correlated with the proximity to differentiating 445 
muscle tissue. Samples co-injected with myoblast were represented as (+ Mb) and 446 
control without myoblasts as (- Mb). *p<0.001, ** p< 0.05, ***p=0.001 447 
 448 





